A new TROP2-targeted ADC showed promising efficacy in an early TNBC trial, with Erika Hamilton, MD, highlighting its potential for broader use in future treatment.
Erika Hamilton, MD
Advertisement
Erika Hamilton, MD, is the director of breast cancer research at Sarah Cannon Research Institute.
Articles by Erika Hamilton, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
ACIP Delayed Hepatitis B Vaccine Schedule Vote Amid Safety Controversy
2
Hereditary Ovarian Cancer Genes Found Beyond Traditionally High-Risk Groups
3
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
4
Medicaid Expansion Associated With Lower Mortality in NSCLC
5
